New drug combo aims to overcome resistance in hard-to-treat lung cancer
Disease control
Completed
This early-phase study tested whether adding the drug copanlisib to the standard immunotherapy durvalumab could help patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study included 11 people who had already received chemotherapy and radiat…
Phase: PHASE1 • Sponsor: Zhonglin Hao • Aim: Disease control
Last updated Apr 29, 2026 01:36 UTC